Drug Trial Radar · NCT03514641
An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential Hypertension
Last checked: Nov 20, 2026Latest source record: Sep 21, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
673
Actual
Start
Oct 18, 2017
Primary completion
Nov 30, 2018
Study completion Nov 30, 2018
Sponsor
- Lead sponsor
- TheracosIndustry
- Sponsor type
- Industry
- First posted
- May 2, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This integrated assessment consists of two studies, 603A and 603B, to be carried out sequentially in a common study population. Participating subjects informed of the trial design and their consent to participate in both studies were to be obtained in a single consent form. Approximately 680 male or female adult subjects were to be enrolled.
Conditions
- Essential Hypertension
Interventions
BexagliflozinDrug
Bexagliflozin tablet, 20 mg
PlaceboDrug
Placebo (inactive) tablet to match the active drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change of the 24 Hour Mean Systolic Blood Pressure From Baseline (Day 1) to Week 12Time frame: Baseline (Day 1) to week 12
- Change of the 24 Hour Mean Systolic Blood Pressure From Cumulative Week 24 to Week 36Time frame: Change from week 24 to week 36
Locations
87 sites in 1 country. Site status is shown where the registry gives one.
Clinical Research Site
Birmingham, Alabama
Clinical Research Site
Birmingham, Alabama
Clinical Research Site
Birmingham, Alabama
Clinical Research Site
Foley, Alabama
Clinical Research Site
Gulf Shores, Alabama
Clinical Research Site
Glendale, Arizona
Clinical Research Site
Mesa, Arizona
Clinical Research Site
Phoenix, Arizona
Clinical Research Site
Tucson, Arizona
Clinical Research Site
Anaheim, California
Clinical Research Site
Bellflower, California
Clinical Research Site
Fair Oaks, California
Clinical Research Site
Fresno, California
Clinical Research Site
Lincoln, California
Clinical Research Site
Los Angeles, California
Clinical Research Site
San Gabriel, California
Clinical Research Site
Santa Rosa, California
Clinical Research Site
Upland, California
Clinical Research Site
Colorado Springs, Colorado
Clinical Research Site
Colorado Springs, Colorado
Clinical Research Site
Denver, Colorado
Clinical Research Site
Golden, Colorado
Clinical Research Site
Stamford, Connecticut
Clinical Research Site
Decatur, Georgia
Clinical Research Site
Decatur, Georgia
Clinical Research Site
Lithonia, Georgia
Clinical Research Site
Chicago, Illinois
Clinical Research Site
Chicago, Illinois
Clinical Research Site
Chicago, Illinois
Clinical Research Site
Avon, Indiana
Clinical Research Site
Evansville, Indiana
Clinical Research Site
Indianapolis, Indiana
Clinical Research Site
Council Bluffs, Iowa
Clinical Research Site
Prairie Village, Kansas
Clinical Research Site
Lexington, Kentucky
Clinical Research Site
Paducah, Kentucky
Clinical Research Site
Versailles, Kentucky
Clinical Research Site
New Orleans, Louisiana
Clinical Research Site
Auburn, Maine
Clinical Research Site
Silver Spring, Maryland
Showing 40 of 87 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.